Guildford, UK, 12 February 2007: ReNeuron Group plc (LSE: RENE.L) today announces that its Founder and Chief Scientific Officer, Dr. John Sinden, will present an overview of the Company’s leading edge stem cell technologies and programmes at the 2nd Annual Stem Cell Summit being held at the Wyndham at Emerald Plaza San Diego in San Diego, California. The presentation is scheduled for Monday, February 12, 2007 at 2:45 PM PST.
Utilizing its proprietary c-mycERTAM adult stem cell expansion platform, ReNeuron is developing groundbreaking cell therapy products. The Company is currently focused on cell therapy treatments designed to reverse the effects of major diseases such as stroke, Parkinson’s disease, diabetes and diseases of the retina.
More information about the conference may be found at www.stemcellsummit.com.
Notes to editors
ReNeuron is a leading, UK-based adult stem cell therapy business. It is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs. ReNeuron has used its c-mycERTAM technology to generate genetically stable neural stem cell lines. This technology platform has multi-national patent protection and is fully regulated by means of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation.
ReNeuron has filed for approval to commence initial clinical studies in the US with its lead ReN001 stem cell therapy for chronic stroke disability. This represents the world’s first such filing concerning a neural stem cell treatment for a major neurological disorder. There are an estimated 50 million stroke survivors worldwide, approximately one half of which are left with permanent disabilities. The annual health and social costs of caring for these patients is estimated to be in excess of £5 billion in the UK and in excess of US$50 billion in the US.
ReNeuron has also generated pre-clinical efficacy data with its ReN005 stem cell therapy for Huntington’s disease, a genetic and fatal neurodegenerative disorder that affects around 1 in 10,000 people. This programme is in pre-clinical development.
In addition to its stroke and Huntington’s disease programmes, ReNeuron is developing stem cell therapies for Parkinson’s disease, Type 1 diabetes and diseases of the retina.
ReNeuron has also leveraged its stem cell technologies into non-therapeutic areas � its ReNcellTM range of cell lines for use in research and in drug discovery applications in the pharmaceutical industry. ReNeuron’s ReNcellTM CX and ReNcellTM VMneural cell lines are marketed worldwide under license by Millipore Corporation.
ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L.
Further information on ReNeuron and its products can be found at www.reneuron.com.
Data sources: UK Stroke Association, American Stroke Association.
|Michael Hunt, Chief Executive Officer|
|John Sinden, Chief Scientific Officer||Tel: 44 (0)1483 302 560|
|Jonathan Birt||Tel: (212) 850-5634|
|Robert Stanislaro||Tel: (212) 850-5657|
The terms �ReNeuron’, �the Company’ or �the Group’ used in this statement refer to ReNeuron Group plc and/or its subsidiary undertakings, depending on the context.